Screener
Cytokinetics CYTK Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Maturities of investments | 482,539 | 549,725 |
| Sales of investments | — | 5,992 |
| Purchases of property and equipment | (10,264) | (9,809) |
| Net cash (used in) provided by investing activities | (361,506) | 158,837 |
| Cash flows from financing activities: | ||
| Repayment of finance lease liabilities | — | (204) |
| Repayment of term loans | (6,329) | (5,378) |
| Payments of royalty obligations | (214) | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's investing cash flow?
- Cytokinetics (CYTK) reported investing cash flow of -$507M in Q2 2026.
- How has Cytokinetics's investing cash flow changed year-over-year?
- Cytokinetics's investing cash flow decreased by 1058.8% year-over-year, from $52.88M to -$507M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Cytokinetics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude